Iovance Biotherapeutics, Inc. IOVA Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s change in accrued liabilities?
- Iovance Biotherapeutics, Inc. (IOVA) reported change in accrued liabilities of -$21.04M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Iovance Biotherapeutics, Inc.'s change in accrued liabilities decreased by 1035.0% year-over-year, from $2.25M to -$21.04M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s change in accrued liabilities?
- Over 3 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s change in accrued liabilities has grown at a 11.8% compound annual growth rate (CAGR), from $20.68M to $28.92M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.